Abstract
Hepatitis B virus (HBV) infections can be prevented or controlled by the host humoral immune response (anti-HBs) directed against the major surface antigen (HBsAg), elicited either naturally or by vaccination. A chronic HBV carrier was found to have high levels of both virus and anti-HBs. Full-length HBV genomes were amplified from the patient's serum, sequenced and cloned. The genome was ‘wild-type’ HBV of genotype C and serotypeadr. The sequence has remained stable, with no signs of emergence of an immune-escape mutant population. To study what was recognized by the patient's serum, viral particles were35S-labelled and then immunoprecipitated by using the patient's serum or control sera. The patient's serum immunoprecipitated theadrHBsAg encoded by his HBV genome poorly, but efficiently recognized HBsAg of serotypeayw. When his HBV genome was modified by a point mutation to express HBsAg of serotypeayr, the patient's serum could recognize the antigen, as well as the control anti-HBs-positive serum. The patient appeared to have made a quasi-monoclonal humoral response to theyepitope. By switching to thedepitope, which requires only a point mutation, the virus could replicate, despite the high levels of anti-HBs. This study underlines the subtleties of virus–host interactions. Implications for HBV vaccination are discussed.

This publication has 34 references indexed in Scilit: